Antiplatelet Cilostazol Is Beneficial in Diabetic and/or Hypertensive Ischemic Stroke Patients

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cerebrovascular Diseases

• Publication date

  2008-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000135654PMID 18511873
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiplatelet Cilostazol Is Effective in the Prevention of Pneumonia in Ischemic Stroke Patients in the Chronic Stage

  2006cited by this paper
• Antiplatelet Drugs In the Secondary Prevention After Stroke: Differential Efficacy in Large Versus Small Vessel Disease? A Subgroup Analysis From ESPS-2

  2006cited by this paper
• Recurrence after Ischemic Stroke in Chinese Patients: Impact of Uncontrolled Modifiable Risk Factors

  2006cited by this paper
• Prevention of Stroke in Patients with Diabetes mellitus and the Metabolic Syndrome

  2005cited by this paper
• Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES)

  2005cited by this paper
• Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial

  2004cited by this paper
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.

  2003cited by this paper
• Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

  2003cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Detection of activated platelets in patients with cerebral infarction at the acute and chronic stages

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells.

  2002cited by this paper
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

  2001cited by this paper
• Primäre Prävention kardiovaskulärer Ereignisse durch ASS und Vitamin E PPP das “Primary Prevention Project”

  2001cited by this paper
• Diabetes and cardiovascular disease

  2000cited by this paper
• Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats.

  2000cited by this paper
• Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.

  2000cited by this paper
• Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.

  2000influential reference
• Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Risk factors for ischemic stroke: Dubbo Study of the elderly.

  1998cited by this paper
• High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study.

  1997cited by this paper
• Aspirin Therapy in Diabetes

  1997cited by this paper
• Stroke recurrence in diabetics. Does control of blood glucose reduce risk?

  1997cited by this paper
• Glucose Intolerance and 22‐Year Stroke Incidence: The Honolulu Heart Program

  1994cited by this paper
• Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study

  1994cited by this paper
• A Multifactorial Analysis of Risk Factors for Recurrence of Ischemic Stroke

  1994cited by this paper
• Diabetes and the risk of stroke.

  1993cited by this paper
• Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.

  1989cited by this paper
• Effect of cilostazol on platelet aggregation and experimental thrombosis

  1988cited by this paper
• Diabetes mellitus: an independent risk factor for stroke?

  1988cited by this paper
• Diabetes and the risk of stroke. The Honolulu Heart Program.

  1987cited by this paper
• Effect of cilostazol on platelet aggregation and experimental thrombosis.

  1985cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper

• European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke

  2024cites this paper
• Long-Term Comparison of Cilostazol versus Clopidogrel in Secondary Prevention of Noncardioembolic Ischemic Stroke

  2023cites this paper
• Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke

  2023cites this paper
• Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

  2023cites this paper
• A novel and ultrasensitive electrochemical biosensor based on MnO2-V2O5 nanorods for the detection of the antiplatelet prodrug agent Cilostazol in pharmaceutical formulations

  2021cites this paper
• Farmakologická sekundární prevence nekardioembolického mozkového infarktu/ /tranzitorní ischemické ataky – současnost a budoucnost Pharmacological Secondary Prevention of Noncardioembolic Cerebral Infarction/transitory Ischemic Attack – Presence and future

  2020cites this paper
• Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society

  2020cites this paper
• Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes　- A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society.

  2020cites this paper
• Progress in the Mechanism and Clinical Application of Cilostazol.

  2019cites this paper
• Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage

  2019cites this paper
• Betanin-enriched red beet extract attenuated platelet activation and aggregation by suppressing Akt and P38 Mitogen-activated protein kinases phosphorylation

  2019cites this paper
• Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness

  2019cites this paper
• Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future.

  2019cites this paper
• Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

  2018cites this paper
• Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.

  2017cites this paper
• Efficacy of antiplatelet therapy for treating lacunar infarct: Meta-analysis

  2017cites this paper
• Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes.

  2017cites this paper
• Antithrombotic treatments in ischemic stroke patients with diabetes mellitus

  2016cites this paper
• Rehabilitation of the Diabetes

  2016cites this paper
• NATIONAL EVIDENCE-BASED GUIDELINE ON SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES Blood pressure lowering , lipid modification and anti-thrombotic therapy

  2015cites this paper
• Diabetes mellitus. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

  2014cites this paper
• The Effects of Comorbidity on the Benefits and Harms of Treatment for Chronic Disease: A Systematic Review

  2014influential citation
• Cilostazol inhibits insulin-stimulated expression of sterol regulatory binding protein-1c via inhibition of LXR and Sp1

  2014cites this paper
• Diabetes mellitus and stroke

  2014cites this paper
• Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2

  2014cites this paper
• Effectiveness of cilostazol in transient ischemic attack refractory to aspirin: A report of two cases

  2013cites this paper
• Platelet antiaggregants in stroke prevention.

  2013cites this paper
• Dilation of porcine retinal arterioles to cilostazol: roles of eNOS phosphorylation via cAMP/protein kinase A and AMP-activated protein kinase and potassium channels.

  2013cites this paper
• INFLAMMATORY INTERACTIONS AND SECRETION IN CARDIAC REMODELING

  2012cites this paper
• Stroke Prevention, Treatment, and Rehabilitation

  2012cites this paper
• Protective effects of cilostazol and levosimendan on lung injury induced by lower limb ischemia-reperfusion Alt ekstremite iskemi reperfüzyonuna bağli akciğer hasarinda silostazol ve levosimendanin koruyucu etkisi

  2012cites this paper
• Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

  2012cites this paper
• Antithrombotic and thrombolytic therapy for ischemic stroke

  2012cites this paper
• New perspectives in antiplatelet therapy.

  2012cites this paper
• Differential Risk Factors for Lacunar Stroke Depending on the MRI (White and Red) Subtypes of Microangiopathy

  2012cites this paper
• Stroke Prevention: Managing Modifiable Risk Factors

  2012cites this paper
• Use of Cilostazol for Secondary Stroke Prevention: An Old Dog with New Tricks?

  2012cites this paper
• Current antithrombotic treatment in East Asia: Some perspectives on anticoagulation and antiplatelet therapy

  2012cites this paper
• Cilostazol improves symptomatic intracranial artery stenosis - Evaluation of cerebral blood flow with single photon emission computed tomography

  2011influential citation
• Cilostazol Versus Aspirin for Secondary Prevention of Vascular Events After Stroke of Arterial Origin

  2011cites this paper
• CONTROVERSY ON THE MANAGEMENT OF ANTICOAGULANTS AND ANTIPLATELET AGENTS FOR SCHEDULED ENDOSCOPY

  2011cites this paper
• Conflicting clinical environment about the management of antithrombotic agents during the periendoscopic period in Japan

  2011cites this paper
• The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus: Principal Results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) Study: A Randomized Trial

  2011cites this paper
• A combined treatment for acute larger lacunar-type infarction.

  2011cites this paper
• Cilostazol: A Drug Particularly Effective for Asians?

  2011cites this paper
• The Brainstem Is at High Risk for Recurrent Noncardioembolic Cerebral Infarction in Association with Diabetes Mellitus: A Hospital-Based Study

  2011cites this paper
• Neurite Outgrowth Mediated by Translation Elongation Factor eEF1A1: A Target for Antiplatelet Agent Cilostazol

  2011cites this paper
• II. Cerebral infarction/transient ischemic attack (TIA).

  2011cites this paper
• Current Therapeutic Strategies to Mitigate the eNOS Dysfunction in Ischaemic Stroke

  2011influential citation
• Cilostazol, Not Aspirin, Reduces Ischemic Brain Injury via Endothelial Protection in Spontaneously Hypertensive Rats

  2011cites this paper
• Predictors for readmission of acute ischemic stroke in Taiwan.

  2011cites this paper
• Japanese guidelines for the management of stroke (2009)

  2010cites this paper
• Chapter 42. Cerebrovascular Disease

  2010cites this paper
• The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus: Principal Results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) Study: A Randomized Trial

  2010cites this paper
• Possible mechanism of preventive effects of coffee intake on the formation of arterial occlusive thrombosis.

  2010cites this paper
• Randomized Trial the Diabetic Atherosclerosis Prevention by Cilostazol ( DAPC ) Study : A Atherosclerosis in Subjects With Type 2 Diabetes Mellitus : Principal Results of The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid

  2010cites this paper
• Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.

  2010cites this paper
• Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives

  2009influential citation
• Antiplatelet therapy after coronary intervention in Asia and Japan

  2009cites this paper
• Nicergoline Increases Serum Substance P Levels in Patients with an Ischaemic Stroke

  2009cites this paper
• Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy

  2009cites this paper
• Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.

  2009cites this paper
• Cilostazol versus aspirin for secondary prevention of vascular events after stroke

  2009cites this paper
• Secondary prevention of stroke.

  2009cites this paper